{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:52Z","timestamp":1783075972095,"version":"3.54.6"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018439","name":"SK Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008475","name":"Hartmann M\u00fcller-Stiftung f\u00fcr Medizinische Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.comppsych.2022.152301","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T10:45:14Z","timestamp":1645872314000},"page":"152301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder"],"prefix":"10.1016","volume":"115","author":[{"given":"Elvira","family":"Tini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Smigielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Romanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wewetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Karwautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Reitzle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Plener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Malzahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heuschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Briegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fleischhaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Hellenschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Imgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kaess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"K\u00f6lch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yin","family":"Reuter-Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rexroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Schulte-K\u00f6rne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Taurines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Maria","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Walitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJMra2033475","article-title":"Depression in adolescents","volume":"385","author":"Miller","year":"2021","journal-title":"N Engl J Med"},{"issue":"10161","key":"10.1016\/j.comppsych.2022.152301_bb0010","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.janxdis.2009.12.004","article-title":"Predictors of functional impairment in pediatric obsessive-compulsive disorder","volume":"24","author":"Storch","year":"2010","journal-title":"J Anxiety Disord"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cpr.2009.09.005","article-title":"Multiple pathways to functional impairment in obsessive\u2013compulsive disorder","volume":"30","author":"Markarian","year":"2010","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0025","first-page":"353","article-title":"Obsessive-compulsive and spectrum disorders in children and adolescents","volume":"29","author":"Geller","year":"2006","journal-title":"Psychiatr Clin"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152301_bb0030","first-page":"173","article-title":"\u201cObsessive-compulsive disorder in children and adolescents,\u201d (in eng)","volume":"108","author":"Walitza","year":"2011","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1024\/1422-4917.31.3.187","article-title":"\u201c[Obsessive-compulsive disorders in children and adolescents--a review],\u201d (in ger)","volume":"31","author":"Jans","year":"2003","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s007870170045","article-title":"\u201cLong-term outcome and prognosis of obsessive-compulsive disorder with onset in childhood or adolescence,\u201d (in eng)","volume":"10","author":"Wewetzer","year":"2001","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152301_bb0045","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1176\/appi.ajp.160.11.1919","article-title":"\u201cWhich SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder,\u201d (in eng)","volume":"160","author":"Geller","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152301_bb0050","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaac.2016.07.768","article-title":"Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder","volume":"55","author":"Varigonda","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"\u201cDouble-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder,\u201d (in eng)","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry"},{"issue":"16","key":"10.1016\/j.comppsych.2022.152301_bb0060","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"\u201cCognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial,\u201d (in eng)","volume":"292","author":"P. O. T. S. P. Team","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152301_bb0065","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.chi.0000233204.51050.f0","article-title":"Sertraline in children and adolescents with major depressive disorder","volume":"45","author":"Donnelly","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1192\/bjp.bp.106.031088","article-title":"Efficacy of antidepressants in juvenile depression: meta-analysis","volume":"193","author":"Tsapakis","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152301_bb0075","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.chi.0000233157.21925.71","article-title":"A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression","volume":"45","author":"Melvin","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152301_bb0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00004583-200209000-00003","article-title":"\u201cSertraline pharmacokinetics and dynamics in adolescents,\u201d (in eng)","volume":"41","author":"Axelson","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0085","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2165\/00003495-199244040-00007","article-title":"\u201cSertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder,\u201d (in eng)","volume":"44","author":"Murdoch","year":"1992","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.comppsych.2022.152301_bb0090","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline","volume":"41","author":"De Vane","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152301_bb0095","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.2174\/092986712800099749","article-title":"\u201cSelective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions,\u201d (in eng)","volume":"19","author":"Mandrioli","year":"2012","journal-title":"Curr Med Chem"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152301_bb0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0090-9556(24)15222-1","article-title":"Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.comppsych.2022.152301_bb0105","series-title":"Human cytochromes mediating sertraline biotransformation: seeking attribution","author":"Greenblatt","year":"1999"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FPC.0000000000000392","article-title":"PharmGKB summary: sertraline pathway, pharmacokinetics","volume":"30","author":"Huddart","year":"2020","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.comppsych.2022.152301_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-020-00455-y","article-title":"Population pharmacokinetics of sertraline in healthy subjects: a model-based meta-analysis","volume":"22","author":"Alhadab","year":"2020","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0120","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1038\/tp.2012.142","article-title":"Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo","volume":"3","author":"Kaddurah-Daouk","year":"2013","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0b013e31827a1aad","article-title":"\u201cThe relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study,\u201d (in eng)","volume":"35","author":"Taurines","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/hup.599","article-title":"Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression","volume":"19","author":"Reis","year":"2004","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007691-200008000-00014","article-title":"\u201cTherapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting,\u201d (in eng)","volume":"22","author":"Lundmark","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"26","key":"10.1016\/j.comppsych.2022.152301_bb0140","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152301_bb0145","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jama.292.7.807","article-title":"Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0b013e31827a1aad","article-title":"The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study","volume":"35","author":"Taurines","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archpsyc.1994.03950040053007","article-title":"Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors","volume":"51","author":"Barr","year":"1994","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0160","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","article-title":"Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy","volume":"37","author":"Alderman","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/apnu.2001.20580","article-title":"\u201cPsychopharmacologic treatment of adolescent depression,\u201d (in eng)","volume":"15","author":"Lynch","year":"2001","journal-title":"Arch Psychiatr Nurs"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1056-4993(18)30452-8","article-title":"Pharmacokinetics in children and adolescents","volume":"4","author":"Clein","year":"1995","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/FTD.0b013e31819f3328","article-title":"\u201cPharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics,\u201d (in eng)","volume":"31","author":"Pichini","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.comppsych.2022.152301_bb0180","series-title":"Neuro-\/Psychopharmaka im Kindes-und Jugendalter: Grundlagen und Therapie","author":"Gerlach","year":"2016"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1124\/jpet.103.060137","article-title":"Developmental expression of human hepatic CYP2C9 and CYP2C19","volume":"308","author":"Koukouritaki","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.comppsych.2022.152301_bb0190","first-page":"2718","article-title":"Pediatric therapeutic drug monitoring for Selective Serotonin Reuptake Inhibitors (SSRIs)","author":"Strawn","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuint.2007.06.025","article-title":"Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs?","volume":"51","author":"Bylund","year":"2007","journal-title":"Neurochem Int"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0200","first-page":"40","article-title":"Pharmacogenomic testing in child and adolescent psychiatry: an evidence-based review","volume":"48","author":"Wehry","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17425255.2019.1584611","article-title":"\u201cPharmacokinetics of serotonergic drugs: focus on OCD,\u201d (in eng)","volume":"15","author":"Marazziti","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1744-6171.2005.00015.x","article-title":"\u201cThe use of selective serotonin reuptake inhibitors in children and adolescents with major depression,\u201d (in eng)","volume":"18","author":"Scahill","year":"2005","journal-title":"J Child Adolesc Psychiatr Nurs"},{"issue":"7","key":"10.1016\/j.comppsych.2022.152301_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","article-title":"\u201cComparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis,\u201d (in eng)","volume":"7","author":"Zhou","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152301_bb0220","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00228-020-02944-7","article-title":"Adverse drug reactions in infants, children and adolescents exposed to antidepressants: a French pharmacovigilance study","volume":"76","author":"Barthez","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0225","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1542\/peds.2009-2317","article-title":"Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts","volume":"125","author":"Schneeweiss","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.comppsych.2022.152301_bb0230","first-page":"1","article-title":"Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants","author":"Eap","year":"2021","journal-title":"World J Biol Psychiatry"},{"issue":"06","key":"10.1016\/j.comppsych.2022.152301_bb0235","first-page":"249","article-title":"Therapeutic drug monitoring in child and adolescent psychiatry","volume":"21","author":"Egberts","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.comppsych.2022.152301_bb0240","series-title":"Antidepressants","first-page":"115","article-title":"Therapeutic drug monitoring of antidepressants","author":"Fiaturi","year":"2018"},{"issue":"15","key":"10.1016\/j.comppsych.2022.152301_bb0245","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.4155\/bio.15.123","article-title":"Current advances in biosampling for therapeutic drug monitoring of psychiatric CNS drugs","volume":"7","author":"Mercolini","year":"2015","journal-title":"Bioanalysis"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152301_bb0250","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.tibtech.2020.03.001","article-title":"On-site therapeutic drug monitoring","volume":"38","author":"Ates","year":"2020","journal-title":"Trends Biotechnol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/clpt.2013.227","article-title":"Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development","volume":"95","author":"Momper","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0265","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.chc.2012.01.005","article-title":"Developmentally informed pharmacotherapy for child and adolescent depressive disorders","volume":"21","author":"Sakolsky","year":"2012","journal-title":"Child Adolesc Psychiatr Clin"},{"issue":"11","key":"10.1016\/j.comppsych.2022.152301_bb0270","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/14740338.2016.1225721","article-title":"Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry","volume":"15","author":"Gerlach","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152301_bb0275","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00702-020-02253-4","article-title":"Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care","volume":"127","author":"Egberts","year":"2020","journal-title":"J Neural Transm"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152301_bb0280","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00702-016-1573-y","article-title":"Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice","volume":"123","author":"Wohkittel","year":"2016","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0285","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FTD.0000000000000398","article-title":"Therapeutic drug monitoring in children and adolescents under pharmacotherapy with olanzapine in daily clinical practice","volume":"39","author":"Fekete","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"06","key":"10.1016\/j.comppsych.2022.152301_bb0290","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1055\/s-0043-109695","article-title":"Relationship between daily dose, serum concentration, and clinical response to quetiapine in children and adolescents with psychotic and mood disorders","volume":"50","author":"Albantakis","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152301_bb0295","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis","volume":"74","author":"Locher","year":"2017","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.comppsych.2022.152301_bb0300","series-title":"Zeitschrift f\u00fcr Kinder-und Jugendpsychiatrie und Psychotherapie","article-title":"Pharmakovigilanz in der Kinder-und Jugendpsychiatrie","author":"Egberts","year":"2014"},{"key":"10.1016\/j.comppsych.2022.152301_bb0305","series-title":"Sicherheit von Psychopharmaka bei Kindern und Jugendlichen in der klinischen Praxis \u2013 Erkenntnisse einer prospektiven Studie","first-page":"4","volume":"vol. 3","author":"Egberts","year":"2020"},{"key":"10.1016\/j.comppsych.2022.152301_bb0310","series-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.comppsych.2022.152301_bb0315","series-title":"The Scientific Proceedings of the 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatry","first-page":"23","article-title":"CAPTN: The pediatric adverse event rating scale","author":"March","year":"2007"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-2-11","article-title":"Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit\/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)","volume":"2","author":"Wehmeier","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/cap.2017.0047","article-title":"A 6-month open-label extension study of vortioxetine in pediatric patients with depressive or anxiety disorders","volume":"28","author":"Findling","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-8-18","article-title":"Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents","volume":"8","author":"Menard","year":"2014","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"01\/02","key":"10.1016\/j.comppsych.2022.152301_bb0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.comppsych.2022.152301_bb0340","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2307\/2532457","article-title":"Assessing proportionality in the proportional odds model for ordinal logistic regression","author":"Brant","year":"1990","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0345","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration\u2013effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152301_bb0350","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1177\/0269881109106899","article-title":"Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism","volume":"24","author":"Umene-Nakano","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0355","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007691-200008000-00014","article-title":"Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting","volume":"22","author":"Lundmark","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0360","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","article-title":"Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients","volume":"45","author":"Br\u00e5ten","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0365","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0300-483X(03)00249-X","article-title":"The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children","volume":"192","author":"Johnson","year":"2003","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0370","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"Obach","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056525","article-title":"Effects of sertraline and fluoxetine on p-glycoprotein at barrier sites: in vivo and in vitro approaches","volume":"8","author":"Kapoor","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0380","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0385","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JCP.0b013e318205e66d","article-title":"Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study","volume":"31","author":"Cherm\u00e1","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.comppsych.2022.152301_bb0390","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0395","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hup.2532","article-title":"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study","volume":"31","author":"Davies","year":"2016","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.comppsych.2022.152301_bb0400","series-title":"Pocket Guide Neuro-\/Psychopharmaka im Kindes-und Jugendalter","first-page":"1","article-title":"Pocket Guide Neuro-\/Psychopharmaka im Kindes-und Jugendalter","author":"Gerlach","year":"2020"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0405","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/cap.2013.0036","article-title":"Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents","volume":"24","author":"Hilt","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152301_bb0410","doi-asserted-by":"crossref","first-page":"983","DOI":"10.12740\/PP\/OnlineFirst\/80998","article-title":"Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts","volume":"52","author":"Woro\u0144","year":"2018","journal-title":"Psychiatr Pol"},{"key":"10.1016\/j.comppsych.2022.152301_bb0415","series-title":"Polypharmazie in der Anwendung von Psychopharmaka in der deutschen Kinder-und Jugendpsychiatrie\u2013h\u00e4ufiger Regel als Ausnahme","author":"Vloet","year":"2018"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152301_bb0420","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1038\/tp.2016.104","article-title":"A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors","volume":"6","author":"Hieronymus","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152301_bb0425","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0430","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","article-title":"Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don\u2019t work","volume":"20","author":"Preskorn","year":"2014","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0435","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.psychres.2004.06.009","article-title":"Psychometric evaluation of the Children\u2019s Yale\u2013Brown obsessive-compulsive scale","volume":"129","author":"Storch","year":"2004","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.comppsych.2022.152301_bb0440","series-title":"Children's depression inventory: Manual","author":"Kovacs","year":"1992"},{"issue":"10","key":"10.1016\/j.comppsych.2022.152301_bb0445","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00004583-200110000-00011","article-title":"Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder","volume":"40","author":"Cook","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"20","key":"10.1016\/j.comppsych.2022.152301_bb0450","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.comppsych.2022.152301_bb0455","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2015.0034","article-title":"Adverse events in very young children prescribed psychotropic medications: preliminary findings from an acute clinical sample","volume":"25","author":"Lee","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152301_bb0460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00004850-199112002-00007","article-title":"Toleration and safety of sertraline: experience worldwide","volume":"6","author":"Doogan","year":"1991","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.comppsych.2022.152301_bb0465","first-page":"1127","article-title":"Possible sertraline-induced extrapyramidal adverse effects in an adolescent","volume":"12","author":"Wang","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152301_bb0470","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ajem.2019.158487","article-title":"Serotonin syndrome from sertraline monotherapy","volume":"38","author":"Duignan","year":"2020","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.comppsych.2022.152301_bb0475","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fpsyt.2019.00294","article-title":"The FDA \u201cblack box\u201d warning on antidepressant suicide risk in young adults: more harm than benefits?","volume":"10","author":"Fornaro","year":"2019","journal-title":"Front Psych"},{"key":"10.1016\/j.comppsych.2022.152301_bb0480","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fpsyt.2020.00018","article-title":"Duty to warn: antidepressant black box suicidality warning is empirically justified","volume":"11","author":"Spielmans","year":"2020","journal-title":"Front Psych"},{"issue":"12","key":"10.1016\/j.comppsych.2022.152301_bb0485","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1176\/appi.ajp.158.12.2008","article-title":"Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder","volume":"158","author":"Rynn","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0490","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004850-199510030-00001","article-title":"Sertraline 50 mg daily: the optimal dose in the treatment of depression","volume":"10","author":"Preskorn","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.comppsych.2022.152301_bb0495","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.290.8.1033","article-title":"Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials","volume":"290","author":"Wagner","year":"2003","journal-title":"Jama"},{"issue":"1\u20132","key":"10.1016\/j.comppsych.2022.152301_bb0500","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/cap.2006.16.103","article-title":"Long-term sertraline treatment of children and adolescents with major depressive disorder","volume":"16","author":"Rynn","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.comppsych.2022.152301_bb0505","doi-asserted-by":"crossref","first-page":"249","DOI":"10.31887\/DCNS.2015.17.3\/ggoodwin","article-title":"The overlap between anxiety, depression, and obsessive-compulsive disorder","volume":"17","author":"Goodwin","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"issue":"1615","key":"10.1016\/j.comppsych.2022.152301_bb0510","doi-asserted-by":"crossref","first-page":"20120435","DOI":"10.1098\/rstb.2012.0435","article-title":"Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive\u2013compulsive disorder as an example of overlapping clinical and genetic heterogeneity","volume":"368","author":"Murphy","year":"2013","journal-title":"Philos Trans Royal Soc B Biol Sci"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1176\/appi.ajp.2020.20111601","article-title":"Harmonizing the neurobiology and treatment of obsessive-compulsive disorder","volume":"178","author":"Goodman","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-018-0128-4","article-title":"Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline","volume":"8","author":"Lissemore","year":"2018","journal-title":"Transl Psychiatry"},{"issue":"7\u20138","key":"10.1016\/j.comppsych.2022.152301_bb0525","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2007.12.009","article-title":"Serotoninergic mechanisms in the treatment of obsessive\u2013compulsive disorder","volume":"13","author":"Goddard","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.comppsych.2022.152301_bb0530","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jad.2017.04.068","article-title":"Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis","volume":"218","author":"Sugarman","year":"2017","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0535","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1370\/afm.349","article-title":"Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis","volume":"3","author":"Arroll","year":"2005","journal-title":"Ann Fam Med"},{"issue":"9","key":"10.1016\/j.comppsych.2022.152301_bb0540","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1177\/0269881117711709","article-title":"Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: systematic review and meta-analysis","volume":"31","author":"Undurraga","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.comppsych.2022.152301_bb0545","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archpsyc.57.1.76","article-title":"Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders","volume":"57","author":"Hoehn-Saric","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2022.152301_bb0550","first-page":"1","article-title":"Langversion der interdisziplin\u00e4ren evidenz-und konsensbasierten S3-Leitlinie f\u00fcr Diagnostik und Therapie von Zwangsst\u00f6rungen im Kindes-und","author":"Walitza","year":"2021","journal-title":"Jugendalter"},{"key":"10.1016\/j.comppsych.2022.152301_bb0555","first-page":"1","article-title":"Therapeutisches Drug Monitoring zur Optimierung der Psychopharmakotherapie von Kindern und Jugendlichen - Update und Leitfaden f\u00fcr die Praxis","author":"Egberts","year":"2021","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0560","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/cap.2018.0160","article-title":"CYP2C19-guided escitalopram and sertraline dosing in pediatric patients: a pharmacokinetic modeling study","volume":"29","author":"Strawn","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.comppsych.2022.152301_bb0565","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/cap.2019.0017","article-title":"Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders","volume":"29","author":"Poweleit","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.comppsych.2022.152301_bb0570","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X22000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X22000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:35:50Z","timestamp":1762115750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X22000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":114,"alternative-id":["S0010440X22000074"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2022.152301","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of sertraline in children and adolescents: A naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2022.152301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152301"}}